Summary

Endometrial Cancer Market Trends and Forecast
The future of the global endometrial cancer market looks promising with opportunities in the hospitals, clinics, and gynecology centers markets. The global endometrial cancer market is expected to grow with a CAGR of 5.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of breast cancer and advancements in treatment techniques.

• Lucintel forecasts that, within the type category, hormone therapy is expected to witness the highest growth over the forecast period.
• Within the application category, hospitals are expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Endometrial Cancer Market
The endometrial cancer market is evolving, driven by emerging trends that reflect progress in treatment options, diagnostics, and patient care. These trends are reshaping how the disease is managed, leading to improved survival rates, more personalized treatment regimens, and greater access to therapies. Below are five key trends that are influencing the market and its future direction.
• Immunotherapy Advancements: Immunotherapy is becoming an increasingly important treatment option for endometrial cancer, especially for patients with mismatch repair-deficient tumors. Checkpoint inhibitors like pembrolizumab and nivolumab have shown promising results in clinical trials, offering a new line of treatment for advanced stages of the disease. As more studies focus on the effectiveness of immunotherapy, it is expected that these treatments will become a mainstay in the management of endometrial cancer. Immunotherapy offers a new approach for patients who may not respond to traditional chemotherapy.
• Targeted Therapy Growth: Targeted therapies that focus on specific molecular and genetic mutations in tumors are gaining traction in the endometrial cancer market. Drugs that target HER2, PI3K, and other key pathways are being developed and tested, providing new hope for patients with aggressive forms of the disease. Personalized medicine is improving the ability to match patients with the right treatments based on their genetic profile. The expansion of targeted therapies is helping improve treatment outcomes and reduce side effects compared to conventional therapies.
• Precision Medicine and Molecular Diagnostics: Precision medicine, which tailors treatments based on individual genetic profiles, is transforming the management of endometrial cancer. Advances in molecular diagnostics are allowing clinicians to identify mutations that may drive cancer growth and choose therapies that are most likely to be effective. This trend is improving the personalization of treatment regimens, allowing for more effective interventions and reducing the risks of adverse effects. Molecular profiling is becoming an essential tool in both clinical practice and research.
• Increasing Focus on Early Detection: Early detection of endometrial cancer remains a critical challenge, but new advancements in screening methods are being developed. Liquid biopsy technologies and genetic testing are being explored as potential tools for identifying endometrial cancer at earlier stages. By detecting cancer earlier, treatment can be started sooner, leading to better outcomes. This focus on early detection, supported by public health initiatives, aims to reduce mortality rates and improve survival chances for patients diagnosed with the disease.
• Integration of Supportive Care and Patient-Reported Outcomes: The integration of supportive care and patient-reported outcomes (PROs) is gaining attention as a way to improve the quality of life for endometrial cancer patients. By focusing on managing symptoms, side effects, and emotional well-being, supportive care is becoming an integral part of treatment. PROs help to assess how patients are responding to therapy from their perspective, leading to more personalized care and better treatment plans. This holistic approach is improving patient satisfaction and long-term outcomes.
The emerging trends in the endometrial cancer market, including advancements in immunotherapy, targeted therapies, precision medicine, early detection, and supportive care, are reshaping the treatment landscape. These developments are leading to more personalized treatment regimens, improved survival rates, and better patient outcomes. As research continues, these trends will play a significant role in transforming the management of endometrial cancer.

Recent Developments in the Endometrial Cancer Market
Recent developments in the endometrial cancer market reflect the ongoing progress in the understanding and treatment of this disease. With new therapies, improved diagnostic tools, and greater patient access to cutting-edge treatments, the market is evolving rapidly. The following sections highlight five key developments that are shaping the landscape of endometrial cancer care.
• Approval of Immunotherapy for Endometrial Cancer: The approval of immunotherapies, such as pembrolizumab and nivolumab, for endometrial cancer has been a significant milestone. These therapies are particularly effective for patients with mismatch repair-deficient tumors and offer a new line of treatment for advanced cases. Their approval has expanded treatment options, especially for patients who do not respond to conventional chemotherapy, providing hope for improved survival and better disease management.
• Advances in Targeted Therapies: The development of targeted therapies, such as PI3K inhibitors and HER2-targeted treatments, has improved the management of aggressive forms of endometrial cancer. These therapies are designed to target specific molecular and genetic mutations in tumors, leading to more personalized treatments. As these therapies become more refined, they are expected to provide greater efficacy and fewer side effects compared to traditional chemotherapy, significantly impacting patient outcomes.
• Growing Adoption of Precision Medicine: The use of precision medicine is becoming more widespread in the treatment of endometrial cancer. Advances in genetic testing and molecular profiling are allowing clinicians to tailor treatments based on the individual genetic makeup of tumors. This trend is helping to optimize treatment regimens, leading to better response rates and reduced toxicity. As precision medicine continues to evolve, it is expected to become the standard approach for managing endometrial cancer.
• Expansion of Liquid Biopsy for Early Detection: Liquid biopsy technologies are showing promise for early detection of endometrial cancer. These non-invasive tests, which analyze circulating tumor DNA or other biomarkers, offer a less invasive alternative to traditional biopsy methods. Liquid biopsies have the potential to detect cancer at earlier stages, allowing for earlier intervention and improving patient outcomes. This development is expected to be a game-changer in the early detection of endometrial cancer.
• Improved Access to Care in Emerging Markets: In emerging markets, access to treatment for endometrial cancer is improving thanks to the increasing availability of generic drugs and biosimilars. Governments and healthcare providers are working to make these life-saving therapies more affordable and accessible to a larger population. This trend is especially important in low- and middle-income countries, where high treatment costs have historically limited access to advanced therapies.
Recent developments in the endometrial cancer market, including the approval of immunotherapies, advances in targeted therapies, and the adoption of precision medicine, are transforming the treatment landscape. These innovations, combined with growing access to early detection methods and care, are improving survival rates and patient outcomes. As research continues to progress, these developments will play a crucial role in shaping the future of endometrial cancer treatment.

Strategic Growth Opportunities in the Endometrial Cancer Market
The endometrial cancer market presents several strategic growth opportunities driven by new treatment approaches, increasing awareness, and advancements in early detection. Companies and healthcare providers have the chance to tap into new markets, develop innovative therapies, and improve patient outcomes. Below are five key growth opportunities in the market.
• Expansion into Emerging Markets: Emerging markets, particularly in Asia and Africa, offer significant growth potential due to the increasing prevalence of endometrial cancer and improving healthcare infrastructure. Pharmaceutical companies have the opportunity to introduce affordable therapies and expand access to treatments through collaborations with local healthcare systems. This will improve survival rates and increase market penetration in these regions.
• Development of Targeted and Personalized Therapies: There is a growing demand for targeted therapies and personalized medicine in the treatment of endometrial cancer. By focusing on therapies that target specific genetic mutations, such as HER2 and PI3K, companies can develop more effective treatments tailored to individual patients. This approach is expected to lead to better outcomes and fewer side effects, presenting a significant growth opportunity in the market.
• Adoption of Immunotherapy: Immunotherapy is an area of rapid growth in the treatment of endometrial cancer. By leveraging checkpoint inhibitors and other immune-modulating agents, companies can offer patients new treatment options that improve survival rates and reduce tumor burden. The expansion of immunotherapy-based treatment regimens represents a major opportunity in the market.
• Integration of Early Detection Technologies: The adoption of early detection technologies, including liquid biopsies and genetic tests, presents an opportunity to improve the management of endometrial cancer. By detecting the disease at earlier stages, patients can benefit from more effective treatments and improved survival outcomes. Companies focused on developing and commercializing these technologies will be positioned for growth in the market.
• Increased Support for Patient Access: Improving patient access to treatment through initiatives such as biosimilars, generics, and pricing strategies will drive market growth. In particular, the expansion of access to treatment in low-income and underserved regions will help to ensure that more patients benefit from the latest therapies. By addressing affordability issues, companies can tap into new patient populations.
Strategic growth opportunities in the endometrial cancer market include expanding into emerging markets, developing targeted therapies, leveraging immunotherapy, integrating early detection technologies, and improving patient access. These opportunities will drive innovation, increase treatment accessibility, and ultimately improve patient outcomes. The market is poised for growth as these trends continue to reshape the treatment landscape.

Endometrial Cancer Market Driver and Challenges
The endometrial cancer market is influenced by several key drivers and challenges, including advancements in treatment options, regulatory factors, economic conditions, and patient access. These elements play a crucial role in shaping the market dynamics and determining the availability and affordability of life-saving therapies. Below, we outline five key drivers and three major challenges that are impacting the market.
The factors responsible for driving the endometrial cancer market include:
1. Technological Advancements in Treatment: Advances in immunotherapy, targeted therapies, and precision medicine are driving growth in the endometrial cancer market. These innovations have led to more effective and personalized treatments that improve patient outcomes. As new therapies continue to be developed, they offer the potential to revolutionize the treatment of advanced endometrial cancer.
2. Increasing Cancer Incidence: The rising incidence of endometrial cancer, particularly among aging populations, is driving demand for new treatments. As more women are diagnosed with the disease, the need for effective therapies grows. This increasing prevalence is fueling research and development efforts to find better treatment options.
3. Regulatory Approvals: The approval of new therapies by regulatory bodies such as the FDA and EMA is expanding treatment options for endometrial cancer patients. These approvals ensure that patients have access to the latest therapies, improving survival rates and offering hope for better outcomes.
4. Rising Healthcare Expenditure: In developed countries, rising healthcare expenditure and improved insurance coverage are increasing patient access to advanced treatments. This is driving market growth by ensuring that more patients can afford life-saving therapies, including immunotherapies and targeted treatments.
5. Growing Focus on Early Detection: Early detection of endometrial cancer through advancements in molecular diagnostics and liquid biopsy technologies is a key driver of market growth. By identifying cancer at earlier stages, treatment becomes more effective, leading to improved survival rates and better patient outcomes.
Challenges in the endometrial cancer market are:
1. High Treatment Costs: Despite advancements, the high cost of many endometrial cancer therapies remains a barrier, particularly in developing countries. These costs limit patient access to treatments, especially in resource-limited settings, where affordability is a significant concern.
2. Limited Access in Rural Areas: In many regions, particularly in emerging markets, there is limited access to advanced treatments due to healthcare infrastructure constraints. Rural areas, in particular, face challenges in providing patients with the necessary care and access to novel therapies.
3. Side Effects and Resistance to Therapy: Some patients experience severe side effects or develop resistance to treatment, which limits the effectiveness of therapies. Managing side effects and overcoming resistance remains a challenge, impacting long-term patient outcomes.
The endometrial cancer market is being shaped by a combination of drivers, including technological advancements, increasing cancer incidence, and regulatory approvals, along with challenges such as high treatment costs, limited access, and treatment resistance. Addressing these challenges while capitalizing on the drivers will be crucial for improving patient outcomes and sustaining market growth.

List of Endometrial Cancer Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies endometrial cancer companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the endometrial cancer companies profiled in this report include-
• Pfizer
• Johnson & Johnson
• Boston Scientific
• GE
• Karl Storz
• Koninklijke Philips
• Celgene
• Lupin
• Lina Medical
• Bayer AG

Endometrial Cancer Market by Segment
The study includes a forecast for the global endometrial cancer market by type, application, and region.
Endometrial Cancer Market by Type [Value from 2019 to 2031]:
• Hysterectomy Techniques
• Radiation
• Hormone Therapy
• Chemotherapy

Endometrial Cancer Market by Application [Value from 2019 to 2031]:
• Hospitals
• Clinics
• Gynecology Centers
• Others

Endometrial Cancer Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Endometrial Cancer Market
The endometrial cancer market has seen significant changes in recent years, driven by advancements in early detection, targeted therapies, and immunotherapy options. These developments are improving patient outcomes and providing new treatment pathways for those with endometrial cancer. The United States, China, Germany, India, and Japan represent major markets in the field, each experiencing distinct trends and regulatory changes that influence access to care. The following sections highlight key developments, emerging trends, and strategic opportunities shaping the endometrial cancer market in these countries.
• United States: In the United States, the endometrial cancer market is experiencing significant advancements, particularly in the field of immunotherapy and targeted therapies. The FDA has approved several new treatments for endometrial cancer, including immune checkpoint inhibitors and molecularly targeted therapies for patients with specific genetic mutations. There has also been an increase in the use of precision medicine, which tailors treatments to the genetic makeup of tumors. Furthermore, the American Cancer Society and other advocacy groups have been working to raise awareness of the disease, contributing to early detection and improved survival rates.
• China: China is seeing rapid growth in the endometrial cancer market as the country experiences an increase in cancer incidence, particularly among older women. Recent regulatory changes have facilitated the approval and use of new treatments, including targeted therapies and immunotherapy. However, the market is still grappling with challenges related to access and affordability, especially in rural areas. As the Chinese healthcare system improves and awareness of the disease rises, it is expected that the adoption of novel therapies for endometrial cancer will continue to grow. Additionally, there is a push for more localized clinical trials to better understand the needs of the Chinese population.
• Germany: Germany is one of the leading countries in Europe when it comes to the treatment of endometrial cancer. The market in Germany benefits from a well-established healthcare system, where patients have access to the latest treatments and therapies. There has been an increased focus on precision medicine and the use of molecular diagnostics to better target therapies to individual patients. Additionally, Germany is one of the leaders in clinical research, with numerous trials investigating novel therapies such as immunotherapy and targeted treatments. However, the high cost of some treatments remains a concern for both patients and healthcare providers.
• India: In India, the endometrial cancer market is evolving, with increasing awareness of the disease leading to more diagnoses and earlier detection. While treatment options are improving, there are still barriers related to affordability and access, particularly in rural areas. The use of targeted therapies and immunotherapies is gaining traction in urban centers, but these treatments remain out of reach for many patients due to their high cost. India is also experiencing growth in the use of generics and biosimilars, which is helping to reduce costs and improve access to life-saving treatments.
• Japan: Japan has made significant strides in the treatment of endometrial cancer, with an increasing emphasis on personalized therapies. The Japanese healthcare system provides rapid access to the latest treatments, including molecularly targeted therapies and immunotherapies. Japan is also a leader in clinical trials, with many new therapies being tested for endometrial cancer. Recent developments have focused on combining immunotherapy with traditional chemotherapy to enhance the efficacy of treatments. The main challenge in Japan remains the high cost of advanced therapies, although insurance systems are working to address this issue by covering more cancer treatments.

Features of the Global Endometrial Cancer Market
Market Size Estimates: Endometrial cancer market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Endometrial cancer market size by type, application, and region in terms of value ($B).
Regional Analysis: Endometrial cancer market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the endometrial cancer market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the endometrial cancer market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.


This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the endometrial cancer market by type (hysterectomy techniques, radiation, hormone therapy, and chemotherapy), application (hospitals, clinics, gynecology centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

ページTOPに戻る

Table of Contents

Table of Contents

1. Executive Summary

2. Global Endometrial Cancer Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: PESTLE Analysis
2.4: Patent Analysis
2.5: Regulatory Environment
2.6: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031
3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
3.2. Global Endometrial Cancer Market Trends (2019-2024) and Forecast (2025-2031)
3.3: Global Endometrial Cancer Market by Type
3.3.1: Hysterectomy Techniques: Trends and Forecast (2019 to 2031)
3.3.2: Radiation: Trends and Forecast (2019 to 2031)
3.3.3: Hormone Therapy: Trends and Forecast (2019 to 2031)
3.3.4: Chemotherapy: Trends and Forecast (2019 to 2031)
3.4: Global Endometrial Cancer Market by Application
3.4.1: Hospitals: Trends and Forecast (2019 to 2031)
3.4.2: Clinics: Trends and Forecast (2019 to 2031)
3.4.3: Gynecology Centers: Trends and Forecast (2019 to 2031)
3.4.4: Others: Trends and Forecast (2019 to 2031)

4. Market Trends and Forecast Analysis by Region from 2019 to 2031
4.1: Global Endometrial Cancer Market by Region
4.2: North American Endometrial Cancer Market
4.2.1: North American Market by Type: Hysterectomy Techniques, Radiation, Hormone Therapy, and Chemotherapy
4.2.2: North American Market by Application: Hospitals, Clinics, Gynecology Centers, and Others
4.2.3: The United States Endometrial Cancer Market
4.2.4: Mexican Endometrial Cancer Market
4.2.5: Canadian Endometrial Cancer Market
4.3: European Endometrial Cancer Market
4.3.1: European Market by Type: Hysterectomy Techniques, Radiation, Hormone Therapy, and Chemotherapy
4.3.2: European Market by Application: Hospitals, Clinics, Gynecology Centers, and Others
4.3.3: German Endometrial Cancer Market
4.3.4: French Endometrial Cancer Market
4.3.5: Spanish Endometrial Cancer Market
4.3.6: Italian Endometrial Cancer Market
4.3.7: The United Kingdom Endometrial Cancer Market
4.4: APAC Endometrial Cancer Market
4.4.1: APAC Market by Type: Hysterectomy Techniques, Radiation, Hormone Therapy, and Chemotherapy
4.4.2: APAC Market by Application: Hospitals, Clinics, Gynecology Centers, and Others
4.4.3: Japanese Endometrial Cancer Market
4.4.4: Indian Endometrial Cancer Market
4.4.5: Chinese Endometrial Cancer Market
4.4.6: South Korean Endometrial Cancer Market
4.4.7: Indonesian Endometrial Cancer Market
4.5: ROW Endometrial Cancer Market
4.5.1: ROW Market by Type: Hysterectomy Techniques, Radiation, Hormone Therapy, and Chemotherapy
4.5.2: ROW Market by Application: Hospitals, Clinics, Gynecology Centers, and Others
4.5.3: Middle Eastern Endometrial Cancer Market
4.5.4: South American Endometrial Cancer Market
4.5.5: African Endometrial Cancer Market

5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
• Competitive Rivalry
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Threat of Substitutes
• Threat of New Entrants

6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Endometrial Cancer Market by Type
6.1.2: Growth Opportunities for the Global Endometrial Cancer Market by Application
6.1.3: Growth Opportunities for the Global Endometrial Cancer Market by Region
6.2: Emerging Trends in the Global Endometrial Cancer Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Endometrial Cancer Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Endometrial Cancer Market
6.3.4: Certification and Licensing

7. Company Profiles of Leading Players
7.1: Pfizer
• Company Overview
• Endometrial Cancer Business Overview
• New Product Development
• Merger, Acquisition, and Collaboration
• Certification and Licensing
7.2: Johnson & Johnson
• Company Overview
• Endometrial Cancer Business Overview
• New Product Development
• Merger, Acquisition, and Collaboration
• Certification and Licensing
7.3: Boston Scientific
• Company Overview
• Endometrial Cancer Business Overview
• New Product Development
• Merger, Acquisition, and Collaboration
• Certification and Licensing
7.4: GE
• Company Overview
• Endometrial Cancer Business Overview
• New Product Development
• Merger, Acquisition, and Collaboration
• Certification and Licensing
7.5: Karl Storz
• Company Overview
• Endometrial Cancer Business Overview
• New Product Development
• Merger, Acquisition, and Collaboration
• Certification and Licensing
7.6: Koninklijke Philips
• Company Overview
• Endometrial Cancer Business Overview
• New Product Development
• Merger, Acquisition, and Collaboration
• Certification and Licensing
7.7: Celgene
• Company Overview
• Endometrial Cancer Business Overview
• New Product Development
• Merger, Acquisition, and Collaboration
• Certification and Licensing
7.8: Lupin
• Company Overview
• Endometrial Cancer Business Overview
• New Product Development
• Merger, Acquisition, and Collaboration
• Certification and Licensing
7.9: Lina Medical
• Company Overview
• Endometrial Cancer Business Overview
• New Product Development
• Merger, Acquisition, and Collaboration
• Certification and Licensing
7.10: Bayer AG
• Company Overview
• Endometrial Cancer Business Overview
• New Product Development
• Merger, Acquisition, and Collaboration
• Certification and Licensing

List of Figures

Chapter 2
Figure 2.1: Classification of the Global Endometrial Cancer Market
Figure 2.2: Supply Chain of the Global Endometrial Cancer Market

Chapter 3
Figure 3.1: Trends of the Global GDP Growth Rate
Figure 3.2: Trends of the Global Population Growth Rate
Figure 3.3: Trends of the Global Inflation Rate
Figure 3.4: Trends of the Global Unemployment Rate
Figure 3.5: Trends of the Regional GDP Growth Rate
Figure 3.6: Trends of the Regional Population Growth Rate
Figure 3.7: Trends of the Regional Inflation Rate
Figure 3.8: Trends of the Regional Unemployment Rate
Figure 3.9: Trends of Regional Per Capita Income
Figure 3.10: Forecast for the Global GDP Growth Rate
Figure 3.11: Forecast for the Global Population Growth Rate
Figure 3.12: Forecast for the Global Inflation Rate
Figure 3.13: Forecast for the Global Unemployment Rate
Figure 3.14: Forecast for the Regional GDP Growth Rate
Figure 3.15: Forecast for the Regional Population Growth Rate
Figure 3.16: Forecast for the Regional Inflation Rate
Figure 3.17: Forecast for the Regional Unemployment Rate
Figure 3.18: Forecast for Regional Per Capita Income
Figure 3.19: Global Endometrial Cancer Market by Type in 2019, 2024, and 2031 ($Billion)
Figure 3.20: Trends of the Global Endometrial Cancer Market ($B) by Type (2019-2024)
Figure 3.21: Forecast for the Global Endometrial Cancer Market ($B) by Type (2025-2031)
Figure 3.22: Trends and Forecast for Hysterectomy Techniques in the Global Endometrial Cancer Market (2019-2031)
Figure 3.23: Trends and Forecast for Radiation in the Global Endometrial Cancer Market (2019-2031)
Figure 3.24: Trends and Forecast for Hormone Therapy in the Global Endometrial Cancer Market (2019-2031)
Figure 3.25: Trends and Forecast for Chemotherapy in the Global Endometrial Cancer Market (2019-2031)
Figure 3.26: Global Endometrial Cancer Market by Application in 2019, 2024, and 2031 ($Billion)
Figure 3.27: Trends of the Global Endometrial Cancer Market ($B) by Application (2019-2024)
Figure 3.28: Forecast for the Global Endometrial Cancer Market ($B) by Application (2025-2031)
Figure 3.29: Trends and Forecast for Hospitals in the Global Endometrial Cancer Market (2019-2031)
Figure 3.30: Trends and Forecast for Clinics in the Global Endometrial Cancer Market (2019-2031)
Figure 3.31: Trends and Forecast for Gynecology Centers in the Global Endometrial Cancer Market (2019-2031)
Figure 3.32: Trends and Forecast for Others in the Global Endometrial Cancer Market (2019-2031)

Chapter 4
Figure 4.1: Trends of the Global Endometrial Cancer Market ($B) by Region (2019-2024)
Figure 4.2: Forecast for the Global Endometrial Cancer Market ($B) by Region (2025-2031)
Figure 4.3: Trends and Forecast for the North American Endometrial Cancer Market (2019-2031)
Figure 4.4: North American Endometrial Cancer Market by Type in 2019, 2024, and 2031 ($Billion)
Figure 4.5: Trends of the North American Endometrial Cancer Market ($B) by Type (2019-2024)
Figure 4.6: Forecast for the North American Endometrial Cancer Market ($B) by Type (2025-2031)
Figure 4.7: North American Endometrial Cancer Market by Application in 2019, 2024, and 2031 ($Billion)
Figure 4.8: Trends of the North American Endometrial Cancer Market ($B) by Application (2019-2024)
Figure 4.9: Forecast for the North American Endometrial Cancer Market ($B) by Application (2025-2031)
Figure 4.10: Trends and Forecast for the United States Endometrial Cancer Market (2019-2031)
Figure 4.11: Trends and Forecast for the Mexican Endometrial Cancer Market (2019-2031)
Figure 4.12: Trends and Forecast for the Canadian Endometrial Cancer Market (2019-2031)
Figure 4.13: Trends and Forecast for the European Endometrial Cancer Market (2019-2031)
Figure 4.14: European Endometrial Cancer Market by Type in 2019, 2024, and 2031 ($Billion)
Figure 4.15: Trends of the European Endometrial Cancer Market ($B) by Type (2019-2024)
Figure 4.16: Forecast for the European Endometrial Cancer Market ($B) by Type (2025-2031)
Figure 4.17: European Endometrial Cancer Market by Application in 2019, 2024, and 2031 ($Billion)
Figure 4.18: Trends of the European Endometrial Cancer Market ($B) by Application (2019-2024)
Figure 4.19: Forecast for the European Endometrial Cancer Market ($B) by Application (2025-2031)
Figure 4.20: Trends and Forecast for the German Endometrial Cancer Market (2019-2031)
Figure 4.21: Trends and Forecast for the French Endometrial Cancer Market (2019-2031)
Figure 4.22: Trends and Forecast for the Spanish Endometrial Cancer Market (2019-2031)
Figure 4.23: Trends and Forecast for the Italian Endometrial Cancer Market (2019-2031)
Figure 4.24: Trends and Forecast for the United Kingdom Endometrial Cancer Market (2019-2031)
Figure 4.25: Trends and Forecast for the APAC Endometrial Cancer Market (2019-2031)
Figure 4.26: APAC Endometrial Cancer Market by Type in 2019, 2024, and 2031 ($Billion)
Figure 4.27: Trends of the APAC Endometrial Cancer Market ($B) by Type (2019-2024)
Figure 4.28: Forecast for the APAC Endometrial Cancer Market ($B) by Type (2025-2031)
Figure 4.29: APAC Endometrial Cancer Market by Application in 2019, 2024, and 2031 ($Billion)
Figure 4.30: Trends of the APAC Endometrial Cancer Market ($B) by Application (2019-2024)
Figure 4.31: Forecast for the APAC Endometrial Cancer Market ($B) by Application (2025-2031)
Figure 4.32: Trends and Forecast for the Japanese Endometrial Cancer Market (2019-2031)
Figure 4.33: Trends and Forecast for the Indian Endometrial Cancer Market (2019-2031)
Figure 4.34: Trends and Forecast for the Chinese Endometrial Cancer Market (2019-2031)
Figure 4.35: Trends and Forecast for the South Korean Endometrial Cancer Market (2019-2031)
Figure 4.36: Trends and Forecast for the Indonesian Endometrial Cancer Market (2019-2031)
Figure 4.37: Trends and Forecast for the ROW Endometrial Cancer Market (2019-2031)
Figure 4.38: ROW Endometrial Cancer Market by Type in 2019, 2024, and 2031 ($Billion)
Figure 4.39: Trends of the ROW Endometrial Cancer Market ($B) by Type (2019-2024)
Figure 4.40: Forecast for the ROW Endometrial Cancer Market ($B) by Type (2025-2031)
Figure 4.41: ROW Endometrial Cancer Market by Application in 2019, 2024, and 2031 ($Billion)
Figure 4.42: Trends of the ROW Endometrial Cancer Market ($B) by Application (2019-2024)
Figure 4.43: Forecast for the ROW Endometrial Cancer Market ($B) by Application (2025-2031)
Figure 4.44: Trends and Forecast for the Middle Eastern Endometrial Cancer Market (2019-2031)
Figure 4.45: Trends and Forecast for the South American Endometrial Cancer Market (2019-2031)
Figure 4.46: Trends and Forecast for the African Endometrial Cancer Market (2019-2031)

Chapter 5
Figure 5.1: Porter’s Five Forces Analysis for the Global Endometrial Cancer Market

Chapter 6
Figure 6.1: Growth Opportunities for the Global Endometrial Cancer Market by Type
Figure 6.2: Growth Opportunities for the Global Endometrial Cancer Market by Application
Figure 6.3: Growth Opportunities for the Global Endometrial Cancer Market by Region
Figure 6.4: Emerging Trends in the Global Endometrial Cancer Market


List of Table

Chapter 1
Table 1.1: Growth Rate (%, 2019-2024) and CAGR (%, 2025-2031) of the Endometrial Cancer Market by Type and Application
Table 1.2: Attractiveness Analysis for the Endometrial Cancer Market by Region
Table 1.3: Global Endometrial Cancer Market Parameters and Attributes

Chapter 3
Table 3.1: Trends of the Global Endometrial Cancer Market (2019-2024)
Table 3.2: Forecast for the Global Endometrial Cancer Market (2025-2031)
Table 3.3: Attractiveness Analysis for the Global Endometrial Cancer Market by Type
Table 3.4: Market Size and CAGR of Various Type in the Global Endometrial Cancer Market (2019-2024)
Table 3.5: Market Size and CAGR of Various Type in the Global Endometrial Cancer Market (2025-2031)
Table 3.6: Trends of Hysterectomy Techniques in the Global Endometrial Cancer Market (2019-2024)
Table 3.7: Forecast for the Hysterectomy Techniques in the Global Endometrial Cancer Market (2025-2031)
Table 3.8: Trends of Radiation in the Global Endometrial Cancer Market (2019-2024)
Table 3.9: Forecast for the Radiation in the Global Endometrial Cancer Market (2025-2031)
Table 3.10: Trends of Hormone Therapy in the Global Endometrial Cancer Market (2019-2024)
Table 3.11: Forecast for the Hormone Therapy in the Global Endometrial Cancer Market (2025-2031)
Table 3.12: Trends of Chemotherapy in the Global Endometrial Cancer Market (2019-2024)
Table 3.13: Forecast for the Chemotherapy in the Global Endometrial Cancer Market (2025-2031)
Table 3.14: Attractiveness Analysis for the Global Endometrial Cancer Market by Application
Table 3.15: Market Size and CAGR of Various Application in the Global Endometrial Cancer Market (2019-2024)
Table 3.16: Market Size and CAGR of Various Application in the Global Endometrial Cancer Market (2025-2031)
Table 3.17: Trends of Hospitals in the Global Endometrial Cancer Market (2019-2024)
Table 3.18: Forecast for the Hospitals in the Global Endometrial Cancer Market (2025-2031)
Table 3.19: Trends of Clinics in the Global Endometrial Cancer Market (2019-2024)
Table 3.20: Forecast for the Clinics in the Global Endometrial Cancer Market (2025-2031)
Table 3.21: Trends of Gynecology Centers in the Global Endometrial Cancer Market (2019-2024)
Table 3.22: Forecast for the Gynecology Centers in the Global Endometrial Cancer Market (2025-2031)
Table 3.23: Trends of Others in the Global Endometrial Cancer Market (2019-2024)
Table 3.24: Forecast for the Others in the Global Endometrial Cancer Market (2025-2031)

Chapter 4
Table 4.1: Market Size and CAGR of Various Regions in the Global Endometrial Cancer Market (2019-2024)
Table 4.2: Market Size and CAGR of Various Regions in the Global Endometrial Cancer Market (2025-2031)
Table 4.3: Trends of the North American Endometrial Cancer Market (2019-2024)
Table 4.4: Forecast for the North American Endometrial Cancer Market (2025-2031)
Table 4.5: Market Size and CAGR of Various Type in the North American Endometrial Cancer Market (2019-2024)
Table 4.6: Market Size and CAGR of Various Type in the North American Endometrial Cancer Market (2025-2031)
Table 4.7: Market Size and CAGR of Various Application in the North American Endometrial Cancer Market (2019-2024)
Table 4.8: Market Size and CAGR of Various Application in the North American Endometrial Cancer Market (2025-2031)
Table 4.9: Trends of the European Endometrial Cancer Market (2019-2024)
Table 4.10: Forecast for the European Endometrial Cancer Market (2025-2031)
Table 4.11: Market Size and CAGR of Various Type in the European Endometrial Cancer Market (2019-2024)
Table 4.12: Market Size and CAGR of Various Type in the European Endometrial Cancer Market (2025-2031)
Table 4.13: Market Size and CAGR of Various Application in the European Endometrial Cancer Market (2019-2024)
Table 4.14: Market Size and CAGR of Various Application in the European Endometrial Cancer Market (2025-2031)
Table 4.15: Trends of the APAC Endometrial Cancer Market (2019-2024)
Table 4.16: Forecast for the APAC Endometrial Cancer Market (2025-2031)
Table 4.17: Market Size and CAGR of Various Type in the APAC Endometrial Cancer Market (2019-2024)
Table 4.18: Market Size and CAGR of Various Type in the APAC Endometrial Cancer Market (2025-2031)
Table 4.19: Market Size and CAGR of Various Application in the APAC Endometrial Cancer Market (2019-2024)
Table 4.20: Market Size and CAGR of Various Application in the APAC Endometrial Cancer Market (2025-2031)
Table 4.21: Trends of the ROW Endometrial Cancer Market (2019-2024)
Table 4.22: Forecast for the ROW Endometrial Cancer Market (2025-2031)
Table 4.23: Market Size and CAGR of Various Type in the ROW Endometrial Cancer Market (2019-2024)
Table 4.24: Market Size and CAGR of Various Type in the ROW Endometrial Cancer Market (2025-2031)
Table 4.25: Market Size and CAGR of Various Application in the ROW Endometrial Cancer Market (2019-2024)
Table 4.26: Market Size and CAGR of Various Application in the ROW Endometrial Cancer Market (2025-2031)

Chapter 5
Table 5.1: Market Presence of Major Players in the Global Endometrial Cancer Market
Table 5.2: Operational Integration of the Global Endometrial Cancer Market

Chapter 6
Table 6.1: New Product Launch by a Major Endometrial Cancer Producer (2019-2024)